Evidence map›Paper›PMID 24849780›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2014

A structure-property relationship study of the well-defined telodendrimers to improve hemocompatibility of nanocarriers for anticancer drug delivery.

Changying Shi, Dekai Yuan, Shikha Nangia, Gaofei Xu, Kit S Lam, Juntao Luo

Abstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Changying ShiDepartment of Pharmacology, SUNY Upstate Cancer Research Institute, State University of New York Upstate Medical University , 750 East Adams Street, Syracuse, New York 13210, United States.
Dekai Yuan
Shikha Nangia
Gaofei Xu
Kit S Lam
Juntao Luo
SUNY Upstate Medical University · USUniversity of California, Davis · USChina Agricultural University · CNSyracuse University · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Size-tunable cancer nanotherapeuticsR01CA140449 · NCI · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2010 to 2014
$1.6M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA140449NCI NIH HHS R01CA140449
6 · The paper itself

Abstract

A series of telodendrimer (a linear polyethyelene glycol-block-dendritic oligo-cholic acid) have been synthesized via a bottom-up approach to optimize the hemocompatibility of the nanocarrier. Numbers of hydrophilic glycerol groups were introduced onto the polar surface of cholic acid to reduce the plasma membrane lytic activity of telodendrimers. An interesting result was observed: only an optimum number of glycerol introduced could reduce the hemolytic properties of the nanocarrier; on the contrary, more glycerols or the amino-glycerol substitution onto cholic acid significantly increased the hemolytic properties of the nanocarriers. To further elucidate the structure-property relationship, the molecular dynamic approach was used to simulate the conformation of the subunits of telodendrimers with different glycerol substitution, and the binding energies and the polar surface areas of the hairpin conformations were calculated to explain the membrane activities of nanocarriers. In addition, these telodendrimer subunits were synthesized and their membrane activities were tested directly, which validated the computational prediction and correlated with the observed hemolytic activity of nanocarriers. The glycerol substitution sustained the facial amphiphilicity of cholic acid, maintaining the superior drug loading capacity (paclitaxel and doxorubicin), stability, cell uptake, and anticancer efficacy of payloads. The in vivo optical imaging study indicated that the optimized nanocarriers can specifically deliver drug molecules to the tumor sites more efficiently than free drug administration, which is essential for the enhanced cancer treatment.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsFemaleHemolysisHT29 CellsHumansMiceMicellesMice, NudeMolecular Dynamics SimulationNanostructuresPaclitaxelAntineoplastic AgentsDoxorubicinDrug CarriersMicellesPaclitaxelPolymers

Identifiers

PMID24849780
PMCPMC4063331
OpenAlexW2320682107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.